A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn’s disease following surgical resection (TOPPIC)

2.50
Hdl Handle:
http://hdl.handle.net/11287/620485
Title:
A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn’s disease following surgical resection (TOPPIC)
Authors:
Satsangi, J.; Kennedy, Nicholas A. ( 0000-0003-4368-1961 ) ; Mowat, C.; Arnott, I.; Keerie, C.; Lewis, S.; Ennis, H.
Abstract:
Crohn’s disease (CD) is a chronic, relapsing, inflammatory bowel disease. Up to 65% of patients with CD require an operation to control the disease within 10 years. Both endoscopic and clinical recurrence is common within 2 years of operation, with re-operation rates cumulating at 5% of patients per year.
Citation:
A randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn’s disease following surgical resection (TOPPIC). Efficacy and Mechanism Evaluation Volume:4 Issue:4 Sep 2017
Publisher:
NIHR
Journal:
Efficacy and Mechanism Evaluation
Issue Date:
Sep-2017
URI:
http://hdl.handle.net/11287/620485
PubMed ID:
28949459
Additional Links:
https://www.journalslibrary.nihr.ac.uk/eme/eme04040/
Type:
Technical report
Language:
en
Appears in Collections:
Gastroenterology; 2017 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSatsangi, J.en
dc.contributor.authorKennedy, Nicholas A.en
dc.contributor.authorMowat, C.en
dc.contributor.authorArnott, I.en
dc.contributor.authorKeerie, C.en
dc.contributor.authorLewis, S.en
dc.contributor.authorEnnis, H.en
dc.date.accessioned2017-11-02T12:13:48Z-
dc.date.available2017-11-02T12:13:48Z-
dc.date.issued2017-09-
dc.identifier.citationA randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn’s disease following surgical resection (TOPPIC). Efficacy and Mechanism Evaluation Volume:4 Issue:4 Sep 2017en
dc.identifier.pmid28949459-
dc.identifier.urihttp://hdl.handle.net/11287/620485-
dc.description.abstractCrohn’s disease (CD) is a chronic, relapsing, inflammatory bowel disease. Up to 65% of patients with CD require an operation to control the disease within 10 years. Both endoscopic and clinical recurrence is common within 2 years of operation, with re-operation rates cumulating at 5% of patients per year.en
dc.language.isoenen
dc.publisherNIHRen
dc.relation.urlhttps://www.journalslibrary.nihr.ac.uk/eme/eme04040/en
dc.subjectWessex Classification Subject Headings::Gastroenterologyen
dc.titleA randomised, double-blind, parallel-group trial to assess mercaptopurine versus placebo to prevent or delay recurrence of Crohn’s disease following surgical resection (TOPPIC)en
dc.typeTechnical reporten
dc.identifier.journalEfficacy and Mechanism Evaluationen
dc.type.versionPublisheden

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.